Alkermes Plc
Change company Symbol lookup
Select an option...
ALKS Alkermes Plc
CPTNW Cepton Equity Warrant Exp 10th Feb 2027 *W EXP 02/10/2027
APPF Appfolio Inc
FMN Federated Hermes Premier Municipal Inc
USCTU TKB Critical Technologies 1
SIEGY Siemens AG
FDBC Fidelity D&D Bancorp Inc
$BUKCHET Bloomberg Coffee Subindex Euro
BMY Bristol-Myers Squibb Co
MLGO MicroAlgo Inc

Health Care : Biotechnology | Small Cap Growth
Based in Ireland
Company profile

Alkermes Public Limited Company is an integrated biopharmaceutical company. It is engaged in researching, developing and commercializing pharmaceutical products that are designed to address unmet medical needs of patients in the fields of neuroscience and oncology. Its portfolio of commercial products focused on alcohol dependence, opioid dependence, schizophrenia and bipolar I disorder and a pipeline of product candidates in development for neurodegenerative disorders and cancer. Its products include ARISTADA, ARISTADA INITIO, LYBALVI and VIVITROL. ARISTADA is an extended-release intramuscular injectable suspension for the treatment of schizophrenia. LYBALVI is a once-daily, oral atypical antipsychotic drug for the treatment of adults with schizophrenia and for the treatment of adults with bipolar I disorder. VIVITROL is a non-narcotic, injectable medication for the treatment of alcohol dependence and for the prevention of relapse to opioid dependence, following opioid detoxification.

Closing Price
Day's Change
0.00 (0.00%)
B/A Size
Day's High
Day's Low
(Below Average)

10-day average volume:

Residential housing demand 'cratered' as mortgage rates spiked, analyst says

7:32 am ET October 24, 2022 (MarketWatch)

By Tomi Kilgore

Mortgage rates above 7% ensure a housing recession, analyst Buck Horne said.

Raymond James analyst Buck Horne lowered ratings on all of the home-builder stocks he covers, as he believes the recent "relentless" climb in mortgage rates has ensured a housing recession.

"Interest rate volatility isn't just slowing the for-sale market," Horne wrote in a note to clients. "We are seeing a broad spectrum reduction in housing demand, including multifamily and SFR [single-family residence]. Net new household formations seem to have come to a standstill."

Horne double downgraded PulteGroup Inc. (PHM), KB Home (KBH) and M.D.C. Holdings Inc. (MDC), moving his ratings down two notches to market perform from strong buy, and cut his ratings on Lennar Corp. (LEN) and Toll Brothers Inc. (TOL) by one notch to market perform from outperform.

He remains bullish on D.R. Horton Inc. (DHI), but less than before, as he downgraded the stock to outperform from strong buy.

"Begrudgingly, we are tapping out on the homebuilders after a relentless [2 percentage point] increase in 30-year mortgage rates over the past 2.5 months," Horne wrote. "Unsurprisingly, numerous anecdotes and indicators...corroborate that the recent parabolic spike in rates has cratered what residual housing demand was still in the market this summer."

Don't miss: Mortgage rates surge to the highest level since April 2002. 'The next several months will undoubtedly be important for the economy and the housing market.'

Also read: U.S. housing starts retreat in September, dragging down U.S. growth.

The iShares U.S. Home Construction exchange-traded fund (ITB) has dropped 12.9% over the past three months and tumbled 36.9% year-to-date. In comparison, the S&P 500 index has lost 6.2% the past three months and fallen 21.3% this year.

Horne said that with average effective mortgage rates now north of 7%, virtually all of the housing affordability metrics he tracks are now in "unprecedented" territory. And with the Federal Reserve indicating that more interest rates hikes are coming as inflation remains stubbornly high, mortgage rates will likely remain high.

Read more: Fed OKs another massive interest-rate high -- and it's not about to stop.

"As such, the housing sector and homebuilders must now brace for a Fed-assured hard landing (you win, Jerome), with significantly lower absorption rates and downward pressure on new home prices," Horne said. "While we still adamantly believe single-family housing in the U.S. remains deeply under-supplied, our experience also tells us that homebuilding stocks will be challenged to outperform so long as home prices remain under pressure." ("Jerome" refers to Fed Chairman Jerome Powell.)

-Tomi Kilgore


(END) Dow Jones Newswires

October 24, 2022 07:32 ET (11:32 GMT)

Copyright (c) 2022 Dow Jones & Company, Inc.

Earnings Calendar and Events Data provided by |Terms of Use| © 2023 Wall Street Horizon, Inc.

Market data accompanied by is delayed by at least 15 minutes for NASDAQ, NYSE MKT, NYSE, and options. Duration of the delay for other exchanges varies.
Market data and information provided by Morningstar.

Options are not suitable for all investors as the special risks inherent to options trading may expose investors to potentially rapid and substantial losses.
Please read Characteristics and Risks of Standard Options before investing in options.

Information and news provided by ,, , Computrade Systems, Inc., ,, and

Copyright © 2023. All rights reserved.